116163-33-8

Basic information

• Product Name: 2-aminomethyl-1,4-di-phenylmethyl piperazine
• CAS NO: 116163-33-8
• Molecular Weight: 295.428
• Mol File: 116163-33-8.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 2-aminomethyl-1,4-di-phenylmethyl piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-aminomethyl-1,4-di-phenylmethyl piperazine(116163-33-8)
• EPA Substance Registry System: 2-aminomethyl-1,4-di-phenylmethyl piperazine(116163-33-8)

Safety Data

• Hazardous Substances Data: 116163-33-8(Hazardous Substances Data)

Upstream product

• 140-28-3 N,N'-Dibenzylethylenediamine 
• 170701-81-2 1,4-dibenzyl-2-piperazinecarbonitrile 
• 471254-15-6 2-Azidomethyl-1,4-dibenzyl-piperazine 
• 24225-89-6 2-chloromethyl-1,4-bis(phenylmethyl)piperazine 
• 188847-59-8 1,4-dibenzyl-piperazine-2-carboxylic acid amide 
• 124257-72-3 2-<(acetylamino)methyl>-1,4-dibenzylpiperazine 
• 122-75-8 N,N'-dibenzylethylenediamine diacetate 

Downstream Products

• 253873-10-8 1,4-dibenzyl-2-(2,2-dimethylpropionylaminomethyl)piperazine 
• 875551-74-9 1,1-dimethylethyl {[1,4-bis(phenylmethyl)-2-piperazinyl]methyl}carbamate 
• 253873-09-5 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-(isopropyloxycarbonylaminomethyl)piperazine 
• 819075-46-2 1,4-dibenzyl-2-(N,N-dipropylaminocarbonylaminomethyl)piperazine 
• 819075-43-9 1,4-dibenzyl-2-(N,N-diethylaminocarbonylaminomethyl)piperazine 
• 819075-27-9 1,4-dibenzyl-2-((2,6-dimethylphenyl)aminocarbonylaminomethyl)piperazine 
• 819075-19-9 1,4-dibenzyl-2-(phenoxycarbonylaminomethyl)piperazine 
• 253873-06-2 1,4-dibenzyl-2-(isopropyloxycarbonylaminomethyl)piperazine 
• 819075-26-8 1,4-dibenzyl-2-(hexylaminocarbonylaminomethyl)piperazine 
• 471254-16-7 N-(1,4-Dibenzyl-piperazin-2-ylmethyl)-4-hydroxy-benzamide 

Relevant articles and documents

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

Piperazine derivatives inhibiting human immunodeficiency virus replication

The invention concerns the use of a piperazine derivative of formula (I) wherein: A and B=C═O, C═S or CR7R8with R7=H, methyl, cyano, cyanomethyl, CO2CH3or (C═O)CH3and R8=H or phenyl; R1to R6=H, OH, or C1-C5alkoxy; X represents: either C═O, O(C═O), O(C═S), O(SO2), NH(C═O), NH(C═S), NH(SO2), S(C═O) or S(C═S), then Y=NR9R10, CR9R10R11in which R9, R10and R11=H, C1-C5alkyl, C2-C5alkenyl, or C2-C5alkynyl or Y=nitrogenous heterocycle comprising 5 to 10 atoms; or X represents O, S, O(C═O)O, NH(C═O)O, or S(C═O)O, then Y=CR9R10R11with R9, R10, R11as above; or one of its pharmaceutically acceptable salts for preparing a medicine inhibiting HIV. The invention is useful for treating HIV infection.

Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication

Excessive levels of PAF and cells of macrophage lineage appear to play an important role in neuronal cell injury, inflammatory syndrome, and HIV replication in CNS resulting in AIDS dementia complex (ADC). The beneficial effects of PAF receptor antagonist